Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement